1. No category

TRANSLATING BASIC SCIENCE INTO
PERSONALIZED CLL TREATMENT
Combined International Workshop of the Clinical Research Unit (KFO)-286
“Exploiting defects in the DNA damage response for the development of novel,
targeted CLL therapy” and the German CLL Study Group (DCLLSG)
March 6th-7th 2015, Bonn, near Cologne
Friday, March 6th 2015
11:00 am
Registration
12:00 – 1:00 pm
1:00 – 2:20 pm
- Welcome lunch Session 1 – Defective survival signaling as a drug target
for CLL therapy
Chair: tbd.; C. Schmitt (Berlin)
The critical role of CLL-associated macrophages
F. Caligaris-Cappio, Milano
tba
M. Keating, Houston
The genomic landscape of CLL: new targets and new
pathways for therapeutic intervention
C. López-Otín, Oviedo
tba
T. Kipps, La Jolla
2:20 – 3:40 pm
Session 2 – Interactions with non-malignant cells in the
tumor microenvironment
Chair: M. Hallek (Cologne), T. Kipps (La Jolla)
B cell receptor signaling in CLL: activated by the
microenvironment, or autonomously?
J. Burger, Houston
Page 1 of 4
Deutsche CLL Studiengruppe
Klinik I für Innere Medizin
Uniklinik Köln
50924 Köln
Für Kurierdienste: Gleueler Straße 176-178, 50935 Köln
Telefon: +49 221 478-88220 • Telefax: +49 221 478-86886
E-Mail: [email protected]
http://www.dcllsg.de
Interactions of CLL with T cells in the immune microenvironment
J. Gribben, London
Microenvironment-addiction: CLL´s achilles heel?
I. Ringshausen, Munich
tba
N. Kay, Rochester
3:40 – 4:10 pm
4:10 – 5:10 pm
- Coffee break Session 3 – Cell death pathways as drug targets for CLL
therapy
Chair: T. Hoppe (Cologne),H. Kashkar (Cologne)
Targeting Inhibitor of Apoptosis (IAP) proteins in CLL
S. Fulda, Frankfurt/Main
Which pro-survival BCL-2 family member should be targeted for
the treatment of which haematological cancer?
A. Strasser; Melbourne
Regulation of the DDR by NOXA ubiquitylation
H. Kashkar, Cologne
5:10 – 6:10 pm
Session 4 – Defective DNA repair pathways as drug targets
for CLL therapy
Chair: Schumacher (Cologne), Herling (Cologne)
Senescence-associated synthetic lethal approaches in
lymphoma therapy
C. Schmitt, Berlin
Structural mechanism and molecular pathology of the Mre11Rad50-Nbs1 complex in the repair of DNA double-strand breaks
K.P. Hopfner, Munich
DNA damage responses in aging and cancer
B. Schumacher, Cologne
6:30 – 7:30 pm
Key Note lecture – Clinical translation
Chair: Hallek (Cologne)
C. Wu, Boston
7:30 – 10.00 pm
Poster viewing/discussion with flying buffet and get
together
Page 2 of 4
Deutsche CLL Studiengruppe
Klinik I für Innere Medizin
Uniklinik Köln
50924 Köln
Für Kurierdienste: Gleueler Straße 176-178, 50935 Köln
Telefon: +49 221 478-88220 • Telefax: +49 221 478-86886
E-Mail: [email protected]
http://www.dcllsg.de
Saturday, March 7th 2015
9:00 – 10:00 am
Session 5 – Learning from mouse models of CLL
Chair: Wunderlich (Cologne), Reinhardt (Cologne)
New microRNAs at 17p. Is p53 the only target in 17p deleted
CLLs?
Yuri Pekarsky, Columbus
Mouse models in the study of CLL pathogenesis
U. Klein, New York
New developments on the role of TNF receptor-associated
factors TRAFs in the etiology of CLL and other B-NHLs
J.M. Zapata, La Jolla
10:00 –10:30 am
10:30 – 11:30 am
- Coffee break Session 6 – New Molecules in treatment of CLL
Chair: tbd
Place of new kinase inhibitors in treatment of CLL
J. Brown, Boston
Treatment strategy with ABT-199
J. Seymour, Melbourne
Place of new monoclonal antibodies in CLL therapy
V. Goede,Cologne
Immunotherapeutic strategies in treatment of CLL (adoptive Tcell therapy, inhibitors of homing etc.)
J. Gribben, London
11:30 – 12:30 pm
12:30 – 2:00 pm
2:00 – 3:00 pm
Satellite symposium pharmaceutical company: Janssen
- Lunch Session 7 – Future Perspectives in CLL
Chair: tbd
New small molecules (IPI-145, AMG-319, ONO-4059, BMS936564 etc) under clinical research
S. O´Brien, Houston
Page 3 of 4
Deutsche CLL Studiengruppe
Klinik I für Innere Medizin
Uniklinik Köln
50924 Köln
Für Kurierdienste: Gleueler Straße 176-178, 50935 Köln
Telefon: +49 221 478-88220 • Telefax: +49 221 478-86886
E-Mail: [email protected]
http://www.dcllsg.de
Factors driving resistance to the new drugs
J. Byrd, Columbus
The role of maintenance treatment in CLL
R. Greil, Salzburg
New / chemo-free strategies in treatment of CLL
M. Keating, Houston (tbc)
Satellite symposium pharmaceutical company: Roche
3:00-3:30
3:30 – 4:00 pm
- Coffee break -
4:00 – (4:30) / 5:00 pm
Satellite symposium pharmaceutical company: Celgene
5:00 – 6:30 pm
Session 8 –Current Study Concepts of International Study
Groups
Chair: tbd
United States
J. Byrd, Columbus
United Kingdom
P. Hillmen, Leeds
Germany
B. Eichhorst, Cologne
6:30 pm -
- Dinner and get together -
Sunday, March 8th 2015
Departure
Page 4 of 4
Deutsche CLL Studiengruppe
Klinik I für Innere Medizin
Uniklinik Köln
50924 Köln
Für Kurierdienste: Gleueler Straße 176-178, 50935 Köln
Telefon: +49 221 478-88220 • Telefax: +49 221 478-86886
E-Mail: [email protected]
http://www.dcllsg.de